Cytokinetics (CYTK)
Cytokinetics Return on Equity: -89.57%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CYTK Return on Equity Rankings
| Overall | 3rd percentile | 3911 of 4055 |
| Sector | 16th percentile | 384 of 458 in Healthcare |
| Industry | 28th percentile | 98 of 138 in Biotechnology |
CYTK Return on Equity Range, Past 5 Years
| Minimum | -89.57% | Mar 2012 |
| Maximum | 33.99% | Sep 2009 |
| Average | -45.46% |
About Return on Equity (ROE)
Click "Learn More" below to see how YCharts calculates Return on Equity.
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities). In other words, ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
You may also be interested in these CYTK related companies
CYTK News
$CYTK forms bearish "Continuation Diamond" chart pattern. http://stks.co/3aqN
about 28 days ago by RecogniaEvents
about 28 days ago by RecogniaEvents
@Jamtrades @seekingalpha when they use the term encouiraging it usually means its crap $CYTK
about 33 days ago by lieberlanz
about 33 days ago by lieberlanz
Cytokinetics (CYTK) Proposed Muscle Troponin Activator Now on FDA's Fast Track
Apr 19, 8:53AM Street Insider
Apr 19, 8:53AM Street Insider
$CYTK forms bearish "Head and Shoulders Top" chart pattern. http://stks.co/3IOW
about 48 days ago by RecogniaEvents
about 48 days ago by RecogniaEvents
$CYTK filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/3BjU
about 56 days ago by MarketBrief
about 56 days ago by MarketBrief
Cytokinetics to Present at the Eleventh Annual Needham Life Sciences Conference
Mar 27, 4:13PM Marketwire
Mar 27, 4:13PM Marketwire
@ChiBullsTrader @ChillzTrading Agree! May add position for that event; already have $CYTK for the same conference.
about 68 days ago by Chilltill
about 68 days ago by Chilltill
$CYTK forms bullish "Diamond Bottom" chart pattern. http://stks.co/2kad
about 81 days ago by RecogniaEvents
about 81 days ago by RecogniaEvents
Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
Feb 02, 4:13PM Street Insider
Feb 02, 4:13PM Street Insider
Cytokinetics, Incorporated Reports Fourth Quarter and Year End Highlights and 2011 Financial Results
Feb 02, 4:00PM Marketwire
Feb 02, 4:00PM Marketwire
Cytokinetics to Announce Fourth Quarter and Year End Results on February 2, 2012
Jan 26, 4:00PM Marketwire
Jan 26, 4:00PM Marketwire
Cytokinetics (CYTK) Reports Positive CK-2017357 Phase II, Part A Dat in ALS Patients
Nov 30, 7:32AM Street Insider
Nov 30, 7:32AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CYTK | 0.93 | +0.02 | +2.20% | 71.03M |
| CVBK | 0.86 | -0.08 | -8.51% | 2.262M |
| CVA | 15.79 | -0.03 | -0.19% | 2.149B |
| CV | 35.13 | -0.02 | -0.06% | 473.55M |
| CUZ | 7.42 | +0.09 | +1.23% | 772.72M |
| CUTR | 6.94 | -0.20 | -2.80% | 96.81M |
| CUT | 16.04 | +0.04 | +0.24% | |
| CURE | 39.59 | +0.00 | +0.00% | |
| CUR | 0.94 | -0.01 | -1.05% | 51.40M |
| CUK | 32.44 | +0.02 | +0.06% | 6.977B |
